Literature DB >> 3103263

Variable free and total valproic acid concentrations in sole- and multi-drug therapy.

J A Cramer, R H Mattson, D M Bennett, C T Swick.   

Abstract

Total and free valproic acid (VPA) serum concentrations differ between patients on sole therapy (SOLE Group) and those taking multiple drugs (MULTI Group). We found significantly higher total and free VPA levels and free fractions in 25 SOLE patients than in 29 MULTI patients, both at morning predose (minimum) and postdose (maximum) testing. Results in SOLE versus MULTI patients were, respectively, as follows: total minimum 70.5 vs. 50.2 micrograms/ml (p less than 0.01); total maximum 106.8 vs. 89.5 micrograms/ml (p less than 0.05); free minimum 9.8 vs. 4.4 micrograms/ml (p less than 0.001); free maximum 18.9 vs. 12.0 micrograms/ml (p less than 0.01). The wide variation in total and free levels suggests the need to monitor VPA levels carefully. Not only does use of other drugs influence VPA kinetics, but the time since last dose also affects levels. Nonlinear binding causes large increases in free levels as total VPA concentration rises. We monitor free and total VPA at minimum and maximum along with evaluation of side effects and seizures for better interpretation of dosage requirements.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3103263     DOI: 10.1097/00007691-198612000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  15 in total

1.  The Pharmacology of Parenteral Valproate.

Authors:  Andres M. Kanner
Journal:  Epilepsy Curr       Date:  2003-05       Impact factor: 7.500

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 3.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 4.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

5.  Interaction between valproate formulation and phenytoin concentrations.

Authors:  Y Suzuki; T Nagai; T Mano; H Arai; R Kodaka; T Matsuoka; Y Itagaki; J Ono; S Okada
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 6.  Pharmacotherapy for Focal Seizures in Children and Adolescents.

Authors:  Clare E Stevens; Carl E Stafstrom
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 7.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

9.  Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid.

Authors:  Ángela Vázquez-Calvo; Miguel A Martín-Acebes; Juan-Carlos Sáiz; Nhi Ngo; Francisco Sobrino; Juan Carlos de la Torre
Journal:  Antiviral Res       Date:  2013-06-02       Impact factor: 5.970

10.  Decreased plasma protein binding of valproate in patients with acute head trauma.

Authors:  G D Anderson; B E Gidal; R J Hendryx; A B Awan; N R Temkin; A J Wilensky; H R Winn
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.